Zhimeng Biopharma
- Total Funding$142 M
OverviewSuggest Edit
Zhimeng Biopharma (上海挚盟医药科技有限公司) is a biotech company developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases. The company develops small molecule drugs to treat epilepsy, pains, and strokes.
| Type | Private | |
| Founded | 2017 | |
| Website | core-biopharma.com |
Latest Updates
| Employees (est.) (Feb 2020) | 12 | |
| Cybersecurity rating | B | More |
Zhimeng Biopharma Financials and Metrics
Summary Metrics
Founding Date | 2017 |
Zhimeng Biopharma total Funding | $142 m |
Zhimeng Biopharma latest funding size | $142 m |
Time since last funding | 3 years ago |
Zhimeng Biopharma investors | Shenzhen Capital Group |
Zhimeng Biopharma's latest funding round in November 2019 was reported to be $142 m. In total, Zhimeng Biopharma has raised $142 m
Zhimeng Biopharma Cybersecurity Score
Zhimeng Biopharma Online and Social Media Presence
Zhimeng Biopharma's Trends
Zhimeng Biopharma Frequently Asked Questions
When was Zhimeng Biopharma founded?
Zhimeng Biopharma was founded in 2017.
How many employees does Zhimeng Biopharma have?
Zhimeng Biopharma has 12 employees.
Who are Zhimeng Biopharma competitors?
Competitors of Zhimeng Biopharma include Surface Ophthalmics, Andromaco and Apnimed.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies